| Populations | Phase 1 | Phase 2 | Registrational | Approved | Current Status |
|---|---|---|---|---|---|
| Advanced Malignant PEComa AMPECT Clinical Trial | Single Agent | First FDA approved therapy for advanced malignant PEComa | |||
 Tumor-agnostic TSC1/TSC2 Inactivating Alterations | TSC1 Arm, Single Agent | Tumor-agnostic pivotal study with independent arms for TSC1 and TSC2 inactivating alterations; open for enrollment | |||
| Tumor-agnostic TSC1/TSC2 Inactivating Alterations | TSC2 Arm, Single Agent | ||||
| Advanced solid tumors or NSCLC with KRASG12C mutation (Phase 1/2) | nab-sirolimus + adagrasib | Collaboration ongoing with  | |||
| Drug | Indication | Stage | Advanced Malignant PEComa AMPECT Clinical Trial First FDA approved therapy for advanced malignant PEComa |
Single Agent | Current Status |
|---|---|---|
| Tumor-agnostic TSC1/TSC2 Inactivating Alterations Tumor-agnostic pivotal study with independent arms for TSC1 and TSC2 inactivating alterations; open for enrollment |
TSC1 Arm, Single Agent | Approved |
| Tumor-agnostic TSC1/TSC2 Inactivating Alterations | TSC2 Arm, Single Agent | Approved |
| Advanced solid tumors or NSCLC with KRASG12C mutation (Phase 1/2) Collaboration ongoing with |
nab-sirolimus + adagrasib | Phase 2 |